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Letters
COMMENT&RESPONSE
In Reply On behalf of the PD REHAB Collaborative Group, we
are pleased that the PD REHAB Trial1 has prompted debate.
The issues raised are common to the 3 letters2-4 and all were
covered in the original article.1
Eligibility was based on the uncertainty principle. Inves-
tigators were mostly uncertain of the value of physiotherapy
and occupational therapy in patients with mild to moderate
Parkinson disease (PD). So, the results of the trial can only be
applied to patients withmild tomoderate disease. This is not
in conflict with our Cochrane review of physical therapies in
PD, which showed short-term benefits inmotor function and
activities of daily living but, importantly, not in quality of life
in more severe disease.5
TheNottinghamExtendedActivitiesofDailyLivingScalewas
usedas theprimaryoutcomeso thatanybenefits couldbecom-
paredwith those in other disease areaswhere it has been used
before(ie,strokeandaging). IthasbeenusedinpreviousPDtrials
andcorrelatedwellwith theUnifiedParkinson’sDiseaseRating
Scaleactivitiesofdaily livingscale inourpilotPD/OTtrial.6This
approach precluded the use of an individualized outcome as
suggestedbydeVriesetal4 in their letter.AlthoughtheNotting-
hamExtendedActivitiesofDailyLivingScaledoesnotdirectly
address gait and transfers, it does assess issues suchaswalking
outside, using public transport, and climbing stairs, which are
ofmore practical use andmore important to patients. Indeed,
ourpatientadvisorygroupsupportedtheuseof theNottingham
ExtendedActivities ofDaily Living as theprimary outcome for
this very reason.
We too were surprised by the low dose of both therapies,
but this is what is being delivered to patients with mild to
moderate PD in the National Health Service (NHS) today. We
do not agree with Mestriner3 that this is nonadherence; it is a
low-dose intervention. We were informed by therapists
before the trial that both physiotherapists and occupational
therapists see such referrals, so they wanted the combined
design of the PD REHAB Trial. A large number of centers
were deliberately secured to aid recruitment and to ensure
that the results could be generalized across the NHS. There-
fore, PD REHAB is a pragmatic trial of standard care in the
NHS and not a study of a novel high-intensity form of
therapy. This is the design that the funder, the NHS Health
Technology Assessment Programme, wanted to inform deci-
sions to be made about the future delivery of such services
within the NHS.
The PDREHABTrial is a high-quality, precise, adequately
powered study that demonstrates that low-dose, patient-
centered, goal-directed physiotherapy and occupational
therapy in early PD is ineffective.We cannot ignore or seek to
discredit important results that we do not find palatable. We
owe it to our patients to deliver the best care possible, so fu-
ture research should explore the development and testing of
more structured and intensive physical and occupational
therapy programs in patients with all stages of PD.
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